Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NBI-1117568 · HTL-0016878

Other · developed by NEUROCRINE BIOSCIENCES

Phase 3 Most advanced trial
NBIX Developer
1 Registered trials

What is NBI-1117568?

NBI-1117568 is an investigational drug studied in Schizophrenia.

At a glance

Also known as
HTL-0016878
Drug type
Other
Therapy area
Psychiatry
Developer
NEUROCRINE BIOSCIENCES (NBIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
TXB4V44U24

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06963034 Phase 3 Schizophrenia Recruiting NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizophrenia

More from NEUROCRINE BIOSCIENCES

Crinecerfont FDA approved Valbenazine FDA approved Chronocort Phase 3 DITEST Phase 1 Luvadaxistat Phase 2 NBI-1065845 Phase 3 NBI-1065890 Phase 2 NBI-1070770 Phase 2 NBI-1117567 Phase 2 NBI-1117570 Phase 2 NBI-827104 Phase 2 NBI-921352 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NBIX page.

Follow NBIX, the company behind NBI-1117568

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.